AbbVie to acquire a J&J-backed brain drugmaker for $1.4B

Buying Aliada Therapeutics would hand AbbVie a clinical-stage Alzheimer’s medicine and a drugmaking technology that may be useful for a variety of brain diseases.

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo

February 12, 2026

Eyesan urges global investors to seize opportunities in 2025 Licensing Round – EnviroNews

February 12, 2026

Source link

AbbVie to acquire a J&J-backed brain drugmaker for $1.4B

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo

Eyesan urges global investors to seize opportunities in 2025 Licensing Round – EnviroNews

‘It’s a hustle’: Fish market folk in Barbados experience more struggle since Hurricane Beryl

Responsible AI practices help companies create value

Responsible AI practices help companies create value

Leave a Reply Cancel reply

RECOMMENDED NEWS

Service Revenue & Mobile Money Drive MTN Rwanda’s Resurgence in 2024

TotalEnergies Secures Four Exploration Permits Offshore Liberia

Charting the last 10 years of the unicorn era

Ring Promo Codes and Discounts: Up to 50% Off

POPULAR NEWS

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

When Will SHIB Reach $1? Here’s What ChatGPT Says

AbbVie to acquire a J&J-backed brain drugmaker for $1.4B

Related posts

‘It’s a hustle’: Fish market folk in Barbados experience more struggle since Hurricane Beryl

Responsible AI practices help companies create value

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS